A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.

J Ovarian Res · 2012 · PMC3408333 · PMID 22732001

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Results of these trials have shown significant prolongation of progression free survival (PFS) with the addition of bevacizumab to standard doublet chemotherapy, with ICON 7 showing also a favorable trend in overall survival (OS), based on which the European Medicines Agency (EMA) has recently approved its use in EOC on 4 th October 2011 [ 15 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.